A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

ClinicalTrials.gov ID: NCT00105443

Public ClinicalTrials.gov record NCT00105443. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Study identification

NCT ID: NCT00105443
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 602 participants

Conditions and interventions

Conditions

Carcinoma, Hepatocellular

Interventions

Sorafenib (Nexavar, BAY43-9006) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2005
Primary completion: Oct 31, 2008
Completion: Oct 31, 2008
Last update posted: Oct 30, 2014

2005 – 2008

United States locations

U.S. sites: 35
U.S. states: 17
U.S. cities: 27

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85054-4502	—
Not listed	Tucson	Arizona	85724	—
Not listed	Los Angeles	California	90057	—
Not listed	Los Angeles	California	90095-7077	—
Not listed	Orange	California	92668-3298	—
Not listed	San Francisco	California	94121	—
Not listed	Stanford	California	94305	—
Not listed	Farmington	Connecticut	06030	—
Not listed	New Haven	Connecticut	06510-8019	—
Not listed	Gainesville	Florida	32610	—
Not listed	Miami	Florida	33136	—
Not listed	Tampa	Florida	33612	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Chicago	Illinois	60611	—
Not listed	Chicago	Illinois	60612	—
Not listed	Lexington	Kentucky	40536	—
Not listed	Ann Arbor	Michigan	48109-0362	—
Not listed	Detroit	Michigan	48202-2689	—
Not listed	St Louis	Missouri	63104	—
Not listed	Omaha	Nebraska	68198-2000	—
Not listed	Manhasset	New York	11030-3876	—
Not listed	New York	New York	10016	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10029	—
Not listed	New York	New York	10032	—
Not listed	Canton	Ohio	44718	—
Not listed	Portland	Oregon	97239	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Philadelphia	Pennsylvania	19140	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Houston	Texas	77030-1502	—
Not listed	Richmond	Virginia	23249	—
Not listed	Seattle	Washington	98104	—
Not listed	Seattle	Washington	98195-6174	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 143 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00105443, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 30, 2014 · Synced Jun 26, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00105443 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →